A common and unsightly skin cancer that can turn deadly has been undetectable for more than a year in a patient treated with a new targeted immune-therapy in a clinical trial at HonorHealth Research Institute.
Patient with advanced skin cancer in remission for more than a year following clinical trial of WTX-124
